Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Tamoxifen is an estrogen receptor antagonist used to prevent recurrence of breast cancer, which may provoke depression and anxiety and increase follicle-stimulating hormone (FSH) to patients. We compared anxiety and depression symptoms and FSH levels who received conventional tamoxifen alone and combination treatment of goserelin, a gonadotropin-releasing hormone (GnRH) analogue, with tamoxifen. Methods: Sixty-four premenopausal women with hormone receptor-positive early-stage breast cancer were included and were assigned randomly to receive either tamoxifen and goserelin combination or tamoxifen alone for 12 months. The participants were evaluated blindly using the Hamilton Depression and Anxiety Rating Scale, the Beck Depression Rating Scale, and the Albany Panic and Phobia Questionnaire (APPQ). Blood FSH levels were assessed at baseline, 6 and 12 months. Results: A significant time×group difference was detected in the agoraphobia trends subscale of the APPQ and in FSH levels. The combination group showed significantly less increases in agoraphobia subscale of APPQ and greater decreases in FSH level than those in the tamoxifen-alone group from baseline to 12 months of treatment. No significant differences for age, tumor grade, body mass index, or family history were found at baseline between the two groups. Conclusion: Our results suggest that the combination treatment of tamoxifen and goserelin resulted in less agoraphobia than tamoxifen alone in premenopausal women with breast cancer, which may associated with FSH suppression of goserelin.
Abstract
Objective: Tamoxifen is an estrogen receptor antagonist used to prevent recurrence of breast cancer, which may provoke depression and anxiety and increase follicle-stimulating hormone (FSH) to patients. We compared anxiety and depression symptoms and FSH levels who received conventional tamoxifen alone and combination treatment of goserelin, a gonadotropin-releasing hormone (GnRH) analogue, with tamoxifen. Methods: Sixty-four premenopausal women with hormone receptor-positive early-stage breast cancer were included and were assigned randomly to receive either tamoxifen and goserelin combination or tamoxifen alone for 12 months. The participants were evaluated blindly using the Hamilton Depression and Anxiety Rating Scale, the Beck Depression Rating Scale, and the Albany Panic and Phobia Questionnaire (APPQ). Blood FSH levels were assessed at baseline, 6 and 12 months. Results: A significant time×group difference was detected in the agoraphobia trends subscale of the APPQ and in FSH levels. The combination group showed significantly less increases in agoraphobia subscale of APPQ and greater decreases in FSH level than those in the tamoxifen-alone group from baseline to 12 months of treatment. No significant differences for age, tumor grade, body mass index, or family history were found at baseline between the two groups. Conclusion: Our results suggest that the combination treatment of tamoxifen and goserelin resulted in less agoraphobia than tamoxifen alone in premenopausal women with breast cancer, which may associated with FSH suppression of goserelin.
참고문헌 (47)
- Dellapasqua S, "Adjuvant endocrine therapy for premenopausal women with early breast cancer", J Clin Oncol, 23, pp.1736~1750 (2005)
- Carlson RW, "Breast cancer", J Nat Compr Cancer Network, 7, pp.122~192 (2009)
- Burstein HJ, "American Society of Clinical Oncology clinical practice guideline : update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer", J Clin Oncol, 28, pp.3784~3796 (2010)
- Goldhirsch A, "Personalizing the treatment of women with early breast cancer : highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013", Ann Oncol, 24, pp.2206~2223 (2013)
- Gjerde J, "Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer", BMC Cancer, 10, pp.313~ (2010)
- Shapiro CL, "Side effects of adjuvant treatment of breast cancer", New Eng J Med, 344, pp.1997~2008 (2001)
- Metindir J, "Ovarian cyst formation in patients using tamoxifen for breast cancer", Jpn J Clin Oncol, 35, pp.607~611 (2005)
- Nicholson RI, "Therapeutic significance and the mechanism of action of the LH-RH agonist ICI 118630 in breast and prostate cancer", J Steroid Biochem, 20, pp.129~135 (1984)
- Moore HC, "Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy", New Eng J Med, 372, pp.923~932 (2015)
- Robertson JF, "The use of gonadotrophin-releasing hormone(GnRH)agonists in early and advanced breast cancer in pre-and perimenopausal women", Eur J Cancer, 39, pp.861~869 (2003)
- Goel S, "LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women", Cochrane Database Syst Rev, (4), pp.CD004562~ (2009)
- Sverrisdottir A, "Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer", Breast Cancer Res Treat, 128, pp.755~763 (2011)
- Francis PA, "Adjuvant ovarian suppression in premenopausal breast cancer", N Engl J Med, 372, pp.436~446 (2015)
- Pagani O, "Adjuvant exemestane with ovarian suppression in premenopausal breast cancer", N Engl J Med, 371, pp.107~118 (2014)
- Minton SE, "Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer", Cancer Control, 9, pp.466~472 (2002)
- Oh JY, "Plasma catecholamine levels before and after paroxetine treatment in patients with panic disorder", Psychiatry Res, 225, pp.471~475 (2015)
- Kim B, "Follicle-stimulating hormone (FSH), current suicidal ideation and attempt in female patients with major depressive disorder", Psychiatry Res, 210, pp.951~956 (2013)
- Baek JH, "Thyroid stimulating hormone and serum, plasma, and platelet brain-derived neurotrophic factor during a 3-month follow-up in patients with major depressive disorder", J Affect Disord, 169, pp.112~117 (2014)
- Ganz PA, "Breast cancer in younger women : reproductive and late health effects of treatment", J Clin Oncol, 21, pp.4184~4193 (2003)
- Cohen LS, "Risk for new onset of depression during the menopausal transition : the Harvard study of moods and cycles", Arch Gen Psychiatry, 63, pp.385~390 (2006)
- van Vliet I, "The MINI-International Neuropsychiatric Interview. A brief structureddiagnostic psychiatric interview for DSM-IV en ICD-10 psychiatric disorders", Tijdschr Psychiatr, 49, pp.393~397 (2007)
- Hamilton M, "Development of a rating scale for primary depressive illness", Br J Soc Clin Psychol, 6, pp.278~296 (1967)
- Hamilton M, "The assessment of anxiety states by rating", Br J Med Psychol, 32, pp.50~55 (1959)
- Beck AT, "Beck depression inventory(BDI)", Arch Gen Psychiatry, 4, pp.561~571 (1961)
- Rapee RM, "Assessment instrument for panic disorder that includes fear of sensation-producing activities : the Albany Panic and Phobia Questionnaire", Anxiety, 1, pp.114~122 (1994)
- Reiss S, "Anxiety sensitivity, anxiety frequency and the prediction of fearfulness", Behav Res Ther, 24, pp.1~8 (1986)
- Hirschfeld RM, "Development and validation of a screening instrument for bipolar spectrum disorder : the Mood Disorder Questionnaire", Am J Psychiatry, 157, pp.1873~1875 (2000)
- Angst J, "The HCL-32 : towards a self-assessment tool for hypomanic symptoms in outpatients", J Affect Disord, 88, pp.217~233 (2005)
- Lim YJ, "Korean Anxiety Sensitivity Index-Revised: its factor structure, reliability, and validity in clinical and nonclinical samples", Depress Anxiety, 24, pp.331~341 (2007)
- Lee EH, "Reliability and validity of the self-report version of the Panic Disorder Severity Scale in Korea", Depress Anxiety, 26, pp.E120~E123 (2009)
- Lee Y, "A study of the reliability and the validity of the BDI, SDS, and MMPI-D scales", Korean J Clin Psychol, 10, pp.98~113 (1991)
- Zimmerman M, "Severity classification on the Hamilton Depression Rating Scale", J Affect Disord, 150, pp.384~388 (2013)
- Asmundson GJ, "Panic disorder and agoraphobia : an overview and commentary on DSM-5 changes", Depress Anxiety, 31, pp.480~486 (2014)
- Azizi-Malekabadi H, "Tamoxifen antagonizes the effects of ovarian hormones to induce anxiety and depression-like behavior in rats", Arquivos de Neuro-Psiquiatria, 73, pp.132~139 (2015)
- Mook D, "Tamoxifen fails to affect central serotonergic tone but increases indices of anxiety in female rhesus macaques", Psychoneuroendocrinology, 30, pp.273~283 (2005)
- Fallowfield L, "Tamoxifen for the prevention of breast cancer : psychosocial impact on women participating in two randomized controlled trials", J Clin Oncol, 19, pp.1885~1892 (2001)
- Ahmann FR, "Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer", J Clin Oncol, 5, pp.912~917 (1987)
- Bromberger JT, "Does risk for anxiety increase during the menopausal transition? Study of women’s health across the nation", Menopause, 20, pp.488~495 (2013)
- Ko CH, "Depression, irritability, and anxiety in women with premenstrual dysphoric disorder", Int J Psychiatry Med, 46, pp.39~55 (2013)
- Britton JR, "Maternal anxiety : course and antecedents during the early postpartum period", Depress Anxiety, 25, pp.793~800 (2008)
- Gordon JL, "Ovarian hormone fluctuation, neurosteroids, and HPA axis dysregulation in perimenopausal depression: a novel heuristic model", Am J Psychiatry, 172, pp.227~236 (2015)
- Antoni MH, "Reduction of cancer-specific thought intrusions and anxiety symptoms with a stress management intervention among women undergoing treatment for breast cancer", Am J Psychiatry, 163, pp.1791~1797 (2006)
- Montgomery J, "Effect of oestrogen and testosterone implants on psychological disorders in the climacteric", Lancet, 1, pp.297~299 (1987)
- Halbreich U, "Role of estrogen in the aetiology and treatment of mood disorders", CNS drugs, 15, pp.797~817 (2001)
- Guimond AJ, "Is anxiety associated with hot flashes in women with breast cancer?", Menopause, 22, pp.864~871 (2015)
- Bruno D, "Management of postmenopausal symptoms in breast cancer survivors", Semin Oncol, 33, pp.696~707 (2006)
- Mitchell ES, "Hot flush severity during the menopausal transition and early postmenopause : beyond hormones", Climacteric, 18, pp.536~544 (2015)